Lakefront Biotherapeutics NV EBITDA Margin Growth & History (LKFT)
Lakefront Biotherapeutics NV's ebitda margin was 32.27% for fiscal 2025.
View full Lakefront Biotherapeutics NV company overviewLakefront Biotherapeutics NV annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 32.27% | +16.56 pp |
| 2024 | 2024-12-31 | 15.72% | −5.57 pp |
| 2023 | 2023-12-31 | 21.29% | +19.68 pp |
| 2022 | 2022-12-31 | 1.60% | — |
| 2020 | 2020-12-31 | −33.46% | −79.12 pp |
| 2019 | 2019-12-31 | 45.66% | +60.73 pp |
| 2018 | 2018-12-31 | −15.07% | +52.22 pp |
| 2017 | 2017-12-31 | −67.29% | −61.65 pp |
| 2016 | 2016-12-31 | −5.64% | — |
Lakefront Biotherapeutics NV quarterly ebitda margin
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 658.96% | +813.84 pp |
| Q1 2026 | 2026-03-31 | −982.92% | −771.24 pp |
| Q4 2025 | 2025-12-31 | 62.22% | — |
| Q3 2025 | 2025-09-30 | 3.40% | — |
| Q2 2025 | 2025-06-30 | −154.88% | — |
| Q1 2025 | 2025-03-31 | −211.68% | — |
Lakefront Biotherapeutics NV ebitda margin trends
Over the last five fiscal years, Lakefront Biotherapeutics NV's ebitda margin increased from −33.46% to 32.27%, a change of +65.73 percentage points. The latest reported quarter, Q2 2026, shows 658.96%.
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lakefront Biotherapeutics NV source filings ↗